Treatment MarketThe global castration-resistant prostate cancer (CRPC) treatment market is poised for substantial growth, ...

Astellas' first-in-class CLDN18.2 drug Vyloy has cleared the FDA. After a positive phase 3 readout, Otsuka is targeting an ...

Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering ...

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

The global ulcerated necrobiosis lipoidica management market is poised for significant growth, with an anticipated valuation ...

Roche Holding AG is willing to pay more than $1 billion to solve one of the biggest challenges of gene therapy: delivery.

The U.S. Food and Drug Administration has approved Vyloy (zolbetuximab-clzb) in combination with fluoropyrimidine- and ...

In 2023, the market is anticipated to be valued at USD 26.64 Billion, marking a significant starting point for a decade-long ...

Seaport Therapeutics Inc. has followed up its recent fundraiser with an oversubscribed $225 million series B financing that will help set it on the path to a phase IIb study of major depressive ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

Bernstein analyst Miki Sogi assigned a Buy rating to Astellas Pharma (ALPMF – Research Report) today and set a price target of ...